Multiple myeloma: Improved outcomes with new therapeutic approaches

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 3, 2012, Pages 330-336

  Eshaghian, Shahrooz ^a   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

Bortezomib; Chemotherapy; Lenalidomide; Multiple myeloma; Steroids; Thalidomide

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; THALIDOMIDE;

HUMAN; MULTIPLE MYELOMA; REVIEW; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84871182296     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283565c56     Document Type: Review

References (96)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta 2010: American Cancer Society. 2010:04
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
3. Rajkumar S, Greipp P.Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999; 13:1295-1314.
4. Gertz M, Ghobrial I, Luc-Harousseau J. Multiple myeloma: biology, standard therapy, and transplant therapy. Biol Blood Marrow Transplant 2009; 15 (1 Suppl):46-52.
5. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med 2004; 351:1860-1873.
6. Rajkumar SV, Kyle RA. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc 2005; 80:1371-1382.
7. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
8. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-2520.
9. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
10. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
11. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myelomainNorth America. N Engl JMed 2007; 357:2133-2142.
12. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123-2132.
13. Mateos M-V, Richardson PG, Schlag R, et al. Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit vs melphalan-pre-dnisone in the phase III VISTA trial in previously untreated multiple myeloma after 3 years' follow-up and extensive subsequent therapy use [abstract 3859]. Blood 2009; 114.
14. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058-3065.
15. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006; 106:1316-1319.
16. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110:3557-3560.
17. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91:929-934.
18. Mikhael JR, Belch AR, Prince HM, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009; 144:169-175.
19. Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29: 587-590.
20. Ma C, Mandrekar SJ, Alberts SR, et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 2007; 59:207-215.
21. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
22. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23:1337-1341.
23. Yellin O, Berenson JR, Kazamel T, et al. A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM) [abstract 8082]. J Clin Oncol 2011; 29.
24. Jakubowiak AJ, Kendall T, Al-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexametha-sone in patients with newly diagnosed myeloma. J Clin Oncol 2009; 27: 5015-5022.
25. Berenson JR, Yellin O, Woytowitz D, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well tolerated frontline regimen. Eur J Haematol 2009; 82:433-439.
26. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892-3901.
27. San Miguel JF, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906-917.
28. Wolf J, Richardson PG, Schuster M, et al. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008; 6:755-760.
29. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreat-ment' approaches in the era of novel agents. Leukemia 2012; 26:73-85.
30. Berenson JR, Yellin O, Bessudo A, et al. An open-label phase 1/2 trial of bendamustine combined with bortezomib for patients with relapsed/refractory multiple myeloma [abstract 8070]. J Clin Oncol 2011; 29:521s.
31. Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012; 53:632-634.
32. Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008; 143:537-540.
33. Fukushima T, Nakamura T, Iwao H, et al. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res 2011; 31:2297-2302.
34. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745-4753.
35. Waterman GN, Yellin O, Swift RA, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Ann Hematol 2011; 90:193-200.
36. Berenson JR, Yellin O, Chen CS, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol 2011; 155:580-587.
37. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, noninferiority study. Lancet Oncol 2011; 12:431-440.
38. Vickrey E, Allen S, Mehta J, et al. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009; 115:229-232.
39. Kim SJ, Kim K, Do YR, et al. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol 2011; 41:353-357.
40. Swaika A, Paulus A, Miller KC, et al. Acyclovir Prophylaxis against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated with Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients. J Support Oncol 2012; 10:155-159.
41. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
42. Yakoub-Agha I, Mary JY, Hulin C, et al. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. Eur J Haematol 2012; 88:249-259.
43. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825-831.
44. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112:3107-3114.
45. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209-1218.
46. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664-3670.
47. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010; 28:3160-3166.
48. Waage A, Gimsing P, Fayers PM, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010; 116:1405-1411.
49. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011; 86:16-22.
50. Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-Analysis. Leukemia 2011; 25:689-696.
51. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-Analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011; 118:1239-1247.
52. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; 28:5101-5109.
53. Morabito F, Gentile M, Mazzone C, et al. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood 2011; 118: 5759-5766.
54. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011; 118:1231-1238.
55. Yang DH, Kim YK, Sohn SK, et al. Induction treatment with cyclophospha-mide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk 2010; 10:62-67.
56. Zervas K, Mihou D, Katodritou E, et al. VAD-Doxil versus VAD-Doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007; 18:1369-1375.
57. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115:1113-1120.
58. Hoshi A, Matsumoto A, Chung J, et al. Activation of coagulation by a thalidomide-based regimen. Blood Coagul Fibrinolysis 2011; 22:532-540.
59. Leonard J, Jayabalan D, Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma. 2007; 48:2330-2337.
60. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalido-mide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29:986-993.
61. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458-3464.
62. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-Agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114:772-778.
63. Baz R, Patel M, Finley-Oliver E, et al. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 2010; 51:1015-1019.
64. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354:2079-2080.
65. Menon SP, Rajkumar SV, Lacy M, et al. Thromboembolic events with lenalido-mide-based therapy for multiple myeloma. Cancer 2008; 112:1522-1528.
66. Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-Analysis. J Thromb Haemost 2011; 9:653-663.
67. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thrombopro-phylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119:933-939.
68. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide-And lenalidomide-Associated thrombosis in myeloma. Leukemia 2008; 22:414-423.
69. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29-37.
70. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 116:3807-3814.
71. Klein U, Neben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol 2011; 90:429-439.
72. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010; 24 (Suppl 1):S13-S19.
73. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase I/II open-label, dose escalation study. Blood 2012; 119:4608-4613.
74. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med 2011; 365:2241-2242.
75. Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119:3003-3015.
76. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119:2764-2767.
77. Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012; 119:2731-2737.
78. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexa-methasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118:2970-2975.
79. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21:2035-2042.
80. Cavallo F, Bringhen S, Milone G, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011; 25:1627-1631.
81. Sinha S, Rajkumar SV, Lacy MQ, et al. Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. Br J Haematol 2010; 148:853-858.
82. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116:5838-5841.
83. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78-88.
84. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116:679-686.
85. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009; 27:5713-5719.
86. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119:4375-4382.
87. Jakubowiak AJ, Griffith KA, Reece DE, et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 2011; 118:535-543.
88. Berenson JR, Yellin O, Kazamel T, et al. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia 2012; 26:1675-1680. doi: 10.1038/leu.2012.51.
89. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99:3163-3168.
90. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27:1788-1793.
91. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289-3294.
92. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after Stem-is Cell Transplantation for Multiple Myeloma. N Engl J Med 2012; 366: 1770-1781.
93. Attal M et al. Maintenance treatment with lenalidomide after transplantation for myeloma: Analysis of secondary malignancies within the IFM 2005-02 trial. Proc International Myeloma Workshop 2011.
94. Palumbo A, Hajek R, Delforge M, et al. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. N Engl J Med 2012; 366:1759-1769.
95. Goldschmidt H, Neben K, Bertsch U, et al. Bortezomib-Based Induction Therapy Followed by Autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) A subgroup analysis of the HOVON-65/GMMG-HD4 Trial [abstract 305]. Proc ASH 2010
96. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119:940-948.